Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: A phase II clinical trial

Leukemia

Volumn 27, Issue 9, 2013, Pages 1902-1909

  Wang, M ^a   Fowler, N ^a   Wagner Bartak, N ^a   Feng, L ^a   Romaguera, J ^a   Neelapu, S S ^a   Hagemeister, F ^a   Fanale, M ^a   Oki, Y ^a   Pro, B ^a   Shah, J ^a   Thomas, S ^a   Younes, A ^a   Hosing, C ^a   Zhang, L ^a   Newberry, K J ^a   Desai, M ^a   Cheng, N ^b   Badillo, M ^a   Bejarano, M ^a   Chen, Y ^a   Young, K H ^a   Champlin, R ^a   Kwak, L ^a   Fayad, L ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

diffuse large B cell lymphoma; follicular lymphoma; lenalidomide; mantle cell lymphoma; rituximab; transformed lymphoma

Indexed keywords

ALKALINE PHOSPHATASE; BORTEZOMIB; CREATININE; LACTATE DEHYDROGENASE; LENALIDOMIDE; RITUXIMAB;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTICLE; BLOOD TOXICITY; BLURRED VISION; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EYE DISEASE; FAINTNESS; FATIGUE; FEMALE; FEVER; FOLLICULAR LYMPHOMA; FOLLOW UP; HEART ARRHYTHMIA; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERMAGNESEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOPENIA; LIVER FUNCTION TEST; LUNG EMBOLISM; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PANCYTOPENIA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PNEUMOTHORAX; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; RECURRENCE; THALIDOMIDE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84883742025     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.95     Document Type: Article

References (43)

1. Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007; 110: 695-708. (Pubitemid 47105409)
2. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. In, 2008 Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri S, Stein H, Thiele J, Vardiman J (eds) WHO Classification of Tumours of Haematopoietic and Lymphoid Systems, Follicular Lymphoma, 4th edn., IARC: Lyon, pp 220-228.
3. Wendum D, Sebban C, Gaulard P, Coiffier B, Tilly H, Cazals D et al. Follicular largecell lymphoma treated with intensive chemotherapy: an analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B-cell lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997; 15: 1654-1663. (Pubitemid 27167406)
4. Bierman PJ. Natural history of follicular grade 3 non-Hodgkin's lymphoma. Curr Opin Oncol 2007; 19: 433-437. (Pubitemid 47356597)
5. Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20\+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008; 9: 105-116.
6. Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L et al. CHOP-like chemotherapy with or without rituximab in young patients with goodprognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 2011; 12: 1013-1022.
7. Fayad L, Thomas D, Romaguera J. Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas. Clin Lymphoma Myeloma 2007; 8(Suppl 2): S57-S62.
8. Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 4952-4957.
9. Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, Justice G et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J Clin Oncol 2009; 27: 5404-5409.
10. Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011; 22: 1622-1627.
11. Ramsay AG, Clear AJ, Kelly G, Fatah R, Matthews J, Macdougall F et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood 2009; 114: 4713-4720.
12. Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, Ottman E, Czuczman MS. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res 2005; 11: 5984-5992. (Pubitemid 41170330)
13. Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20\+ tumor cells. Clin Cancer Res 2008; 14: 4650-4657.
14. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Roth M, Vaughn M, Knight J et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the antitumour activity of rituximab in vivo. Br J Haematol 2008; 140: 36-45. (Pubitemid 350233246)
15. Zhang L, Qian Z, Cai Z, Sun L, Wang H, Bartlett JB et al. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol 2009; 84: 553-559.
16. Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 2012; 13: 716-723.
17. Zinzani PL, Pellegrini C, Gandolfi L, Stefoni V, Quirini F, Derenzini E et al. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin Lymphoma Myeloma Leuk 2011; 11: 462-466.
18. Samaniego F, Hagemeister F, Mclaughlin P, Kwak LW, Romaguera J, Fanale MA et al. High response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin lymphoma, including those meeting GELF criteria. J Clin Oncol 2011; 29: 8030.
19. Leonard J, Jung S-H, Johnson JL, Bartlett N, Blum KA, Cheson BD et al. CALGB 50401: A randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma. ASCO Meeting Abstr 2012; 30: 8000.
20. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
21. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586. (Pubitemid 350002966)
22. Visco C, Li Y, Xu-Monette ZY, Miranda RN, Green TM, Tzankov A et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia 2012; 26: 2103-2113.
23. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10. (Pubitemid 19099520)
24. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28: 4184-4190.
25. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-1947. (Pubitemid 34651353)
26. Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198: 851-862. (Pubitemid 37152922)
27. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511. (Pubitemid 30082188)
28. Savage KJ, Monti S, Kutok JL, Cattoretti G, Neuberg D, De Leval L et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003; 102: 3871-3879. (Pubitemid 37486965)
29. Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 2008; 105: 13520-13525.
30. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008; 359: 2313-2323.
31. Thieblemont C, Briere J, Mounier N, Voelker HU, Cuccuini W, Hirchaud E et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol 2011; 29: 4079-4087.
32. Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F, Macon WR et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer 2011; 117: 5058-5066.
33. Bernstein SH, Burack WR. The incidence, natural history, biology, and treatment of transformed lymphomas. Hematology Am Soc Hematol Educ Program 2009 532-541.
34. Reddy NM, Hernandez-Ilizaliturri FJ, Czuczman MS. The use of the immunomodulatory drug, lenalidomide (Revlimid(R)) as a novel strategy to overcome acquired antibody resistance in rituximab-resistant non-Hodgkin's lymphoma (NHL) cell lines. AACR Meet Abstr 2006; 2006: 154a.
35. Salles G, Seymour JF, Offner F, Lopez-Guillermo A, Belada D, Xerri L et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011; 377: 42-51.
36. Forstpointner R, Unterhalt M, Dreyling M, Bock HP, Repp R, Wandt H et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006; 108: 4003-4008. (Pubitemid 44920177)
37. Vidal L, Gafter-Gvili A, Salles G, Dreyling MH, Ghielmini M, Hsu Schmitz SF et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2011; 103: 1799-1806.
38. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 3121-3127. (Pubitemid 46638950)
39. Gisselbrecht C, Glass B, Laurent G, Gill DS, Linch MD, Trneny M et al. Maintenance with rituximab after autologous stem cell transplantation in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL): CORAL final analysis. ASCO Meet Abstr 2011; 29: 8004.
40. Li YJ, Xia ZJ, Li S, Chen XQ, Xia Y, Xu F et al. Maintenance rituximab versus observation after R-CHOP or R-EPOCH in patients with untreated poor-prognosis diffuse large B-cell lymphoma and grade III follicular lymphoma. ASCO Meet Abstr 2010; 28: 8084.
41. Raefsky EL, Greco FA, Spigel DR, Doss HH, Farley C, Saez R et al. Brief duration rituximab(R)/chemotherapy (CNOP or CVP) followed by maintenance rituximab in elderly/poor performance status patients (pts) with diffuse large B-cell lymphoma (DLBCL): A phase II trial of the Minnie Pearl Cancer Research Network. ASCO Meet Abstr 2006; 24: 7577.
42. Fowler N, Hagemeister F, McLaughlin P, Kwak L, Romaguera J, Fanale M et al. Lenalidomide plus rituximab is a highly effective and well-tolerated biologic therapy in untreated indolent B cell non-Hodgkin's lymphoma. Ann Oncol 2011; 22: 128-129.
43. Dutia M, Deroock I, Reed-Pease C, Tuscano J. Lenalidomide plus rituximab leads to a high rate of durable responses in patients with relapsed/refractory indolent non-Hodgkin's lymphoma. Ann Oncol 2011; 22: 186-186.